Press Resease

Cancer Drugs Market - Global Industry Analysis

Cancer Drugs Market By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Hormone Therapy and Others), By Cancer Type (For Breast Cancer, Blood Cancer, Gastrointestinal Cancer, Prostate Cancer, Skin Cancer, Lung Cancer and Other): Global Industry Perspective, Comprehensive Analysis And Forecast, 2021-2028

Published Date: 10-May-2021 Category: Healthcare Report Format : PDF Pages: 150 Report Code: ZMR-490 Status : Published

The global cancer drugs market accounted for USD 155.12 Billion in 2020 and is expected to reach USD 292.80 Billion by 2028, growing at a CAGR of 9.5 % from 2021 to 2028.

Description

Market Overview

The global cancer drugs market accounted for USD 155.12 Billion in 2020 and is expected to reach USD 292.80 Billion by 2028, growing at a CAGR of 9.5 % from 2021 to 2028.

Cancer is an alarming disease that causes cellular damage and affects the human body’s immune system. Cancer drugs are used in many ways; by therapy like Chemotherapy, Immunotherapy, Targeted Therapy, Hormone Therapy and Others for curing all types of Cancers like Prostate Cancer, Skin Cancer, Breast Cancer, Blood Cancer, Lung Cancer, Gastrointestinal Cancer, and Other Cancer. Cancer, unlike many other diseases requires constant monitor and has different stages as well. Each stage demands a different drug to cure the disease. With the help of extensive research and study, the cancer drugs are modified and matched to suit the patient’s requirement.

With technological advancements and increasing importance of artificial intelligence, cancer drugs market can reach a breakthrough with quality in the pharma industry. Media has played a pivotal role, keeping the general public aware about the treatments available in case of malignancy. Supportive government norms and schemes with abundant investment for fighting cancer have paved way to success for the cancer drugs market. Many companies and non-government organizations also run fundraisers and campaigns creating an amicable environment for the cancer drugs market. With due consideration to all the factors mentioned earlier, the market is expected to flourish in the years to come.

COVID-19 Impact Analysis

The cancer drugs market has undergone a fall due to the various shutdowns and government orders as a view to contain the spread of COVID 19. The entire pharmaceutical industry was on a halt during stringent lockdown as all the attention shifted drastically on COVID 19. The restrictions imposed by various nations to contain COVID had stopped the supply chains and exchange of significant medical ingredients across countries, causing a downfall in the market. The pharmaceutical industry has now shifted all the investment, research to the focus of COVID19. Cancer industry Chemotherapy depends on the spending having made on R&D, but post pandemic, the spending has shifted for COVID.

Global Cancer Drugs Market

Growth Factors

Increasing cancer cases and technological advancements are the main driving factors in the cancer drugs market. With growing awareness and advertisement, the general public are fully aware of the treatment and consequences of the disease. Consumer spending on healthcare has increased with time and patients are willing to spend more on cancer treatment. As a result, the medical industry has a Chemotherapy share of investment to be spent on the R&D for producing advanced drugs and treatment. Furthermore, drugs development and therapies for cancer and government striving on improvement of healthcare industry are expected to drive the market for cancer drugs.

On the other hand, high treatment costs, unmatched government norms, and huge investment in the trials therapies for cancer treatment are some of the major factors restraining the growth for global cancer drugs market. 

Furthermore, the patients can choose whether they would want to receive the drugs in the hands from a specialty distributor or a specialty pharmacy. However, specialty pharmacy being the traditional approach holds dominance as it proved to be most efficient and trusted among the patients, holding major control over the drug supply chain.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Cancer therapy Segment Analysis Preview

The cancer drugs market uses various therapy for curing cancer like; Immunotherapy, Targeted Therapy, Chemotherapy, Hormone Therapy and Others. Each therapy is prescribed at various stages of cancer for different human body types. Every patient’s immune system reacts differently to the drugs and hence the classification of therapies is justified.

Immunotherapy and Chemotherapy held the highest share in the global market. Both these therapies have high adoption rate owing to their high effectiveness compared to other therapies. The investment costs on the research and development is anticipated to surge with the rising cancer cases.

Cancer type Segment Analysis Preview

Cancer provides an environment to allow the growth of certain abnormal cells in the body of the affected person. Based on the area of affect, the cancer disease is categorized into Gastrointestinal Cancer, Breast Cancer, Blood Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, and Others. The segment which led the market is breast cancer owing to increasing awareness, in-depth R&D investments by leading companies and surged breast cancer therapeutics are the various factors responsible for faster growth of market.

Regional Analysis Preview

On the basis of geography, North America holds a majority of xx% share backed by extensive government support for the field of drug development and is expected to withhold the supremacy in the coming years.  With promising healthcare facility and favorable insurance schemes, the cancer drugs market have propelled in the North America and Europe.

With increasing new players in the market and developing cancer incidence, regular hike in the cancer drugs market is guaranteed. However, Asia pacific is expected to grow in the future with pushing more of its attention on R&D in the health sector and holding the most aged population in the world.

 Key Market Players & Competitive Landscape

Some of the key players in the global cancer drugs market are Amgen, Bayer Healthcare AG, CELGENE CORPORATION, GlaxoSmithKline, ARIAD Pharmaceuticals, Inc., Eli Lilly and Company, Novartis, Hoffmann-La Roche Ltd., AstraZeneca, Boehringer Ingelheim GmbH, Pfizer and Teva Pharmaceuticals Industries.

The Cancer Drugs market is segmented as follows:

By Cancer therapy

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Hormone therapy

By Cancer type

  • Breast Cancer
  • Blood Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Skin Cancer
  • Lung Cancer

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content


List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Cancer Therapy
FIG NO. 2. Market Attractiveness Analysis, By Cancer Type
FIG NO. 3. Market Attractiveness Analysis, By Distribution Channel
FIG NO. 4. Market Attractiveness Analysis, By Region
FIG NO. 5. Global Cancer Drugs Market Revenue, 2016 – 2028 (USD Billion)
FIG NO. 6. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 7. Market Revenue Share, By Cancer Therapy, 2020 & 2028
FIG NO. 8. Global Cancer Drugs Market for Immunotherapy, Revenue (USD Billion) 2016 – 2028
FIG NO. 9. Comparative Revenue Analysis of Cancer Drugs Market for Immunotherapy, By Country, 2020 & 2028
FIG NO. 10. Global Cancer Drugs Market for Targeted Therapy, Revenue (USD Billion) 2016 – 2028
FIG NO. 11. Comparative Revenue Analysis of Cancer Drugs Market for Targeted Therapy, By Country, 2020 & 2028
FIG NO. 12. Global Cancer Drugs Market for Chemotherapy, Revenue (USD Billion) 2016 – 2028
FIG NO. 13. Comparative Revenue Analysis of Cancer Drugs Market for Chemotherapy, By Country, 2020 & 2028
FIG NO. 14. Global Cancer Drugs Market for Hormone therapy , Revenue (USD Billion) 2016 – 2028
FIG NO. 15. Comparative Revenue Analysis of Cancer Drugs Market for Hormone therapy , By Country, 2020 & 2028
FIG NO. 16. Market Revenue Share, By Cancer Type, 2020 & 2028
FIG NO. 17. Global Cancer Drugs Market for Immunotherapy, Revenue (USD Billion) 2016 – 2028
FIG NO. 18. Comparative Revenue Analysis of Cancer Drugs Market for Immunotherapy, By Country, 2020 & 2028
FIG NO. 19. Global Cancer Drugs Market for Targeted Therapy, Revenue (USD Billion) 2016 – 2028
FIG NO. 20. Comparative Revenue Analysis of Cancer Drugs Market for Targeted Therapy, By Country, 2020 & 2028
FIG NO. 21. Global Cancer Drugs Market for Chemotherapy, Revenue (USD Billion) 2016 – 2028
FIG NO. 22. Comparative Revenue Analysis of Cancer Drugs Market for Chemotherapy, By Country, 2020 & 2028
FIG NO. 23. Market Revenue Share, By Distribution Channel, 2020 & 2028
FIG NO. 24. Global Cancer Drugs Market for Stores, Revenue (USD Billion) 2016 – 2028
FIG NO. 25. Comparative Revenue Analysis of Cancer Drugs Market for Stores, By Country, 2020 & 2028
FIG NO. 26. Global Cancer Drugs Market for Online, Revenue (USD Billion) 2016 – 2028
FIG NO. 27. Comparative Revenue Analysis of Cancer Drugs Market for Online, By Country, 2020 & 2028
FIG NO. 28. Global Cancer Drugs Market for Hormone therapy , Revenue (USD Billion) 2016 – 2028
FIG NO. 29. Comparative Revenue Analysis of Cancer Drugs Market for Hormone therapy , By Country, 2020 & 2028
FIG NO. 30. Global Cancer Drugs Market Revenue Share, By Region, 2020 & 2028
FIG NO. 31. North America Cancer Drugs Market Revenue, 2016 - 2028 (USD Billion)
FIG NO. 32. Porter’s Five Forces Analysis for Global Cancer Drugs Market
FIG NO. 33. PEST Analysis for Global Cancer Drugs Market
FIG NO. 34. Pricing Analysis for Global Cancer Drugs Market
FIG NO. 35. Value Chain Analysis for Global Cancer Drugs Market
FIG NO. 36. Company Share Analysis, 2019
FIG NO. 37. Radar Determinant Chart, 2019
FIG NO. 38. Company Strategic Developments – Heat Map Analysis
FIG NO. 39. Emerson Electric Co Business Segment Revenue Share, 2020 (%)
FIG NO. 40. Emerson Electric Co Geographical Segment Revenue Share, 2020 (%)
FIG NO. 41. Market Channels
FIG NO. 42. Marketing Channel Development Trend
FIG NO. 43. Growth in World Gross Product, 2008-2018
FIG NO. 44. Research Methodology – Detailed View
FIG NO. 45. Research Methodology


List of Tables 

TABLE NO. 1. Global Cancer Drugs Market: Snapshot
TABLE NO. 2. Quarterly Cancer Drugs Market Revenue by Region, 2020
TABLE NO. 3. Quarterly Cancer Drugs Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
TABLE NO. 6. Global Cancer Drugs Market for Immunotherapy, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 7. Global Cancer Drugs Market for Targeted Therapy, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 8. Global Cancer Drugs Market for Chemotherapy, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 9. Global Cancer Drugs Market for Hormone therapy , by Region, 2016 – 2028 (USD Billion)
TABLE NO. 10. Global Cancer Drugs Market for Immunotherapy, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 11. Global Cancer Drugs Market for Targeted Therapy, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 12. Global Cancer Drugs Market for Chemotherapy, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 13. Global Cancer Drugs Market for Stores, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 14. Global Cancer Drugs Market for Online, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 15. Global Cancer Drugs Market for Hormone therapy , by Region, 2016 – 2028 (USD Billion)
TABLE NO. 16. Global Cancer Drugs Market Revenue, By Region, 2016 – 2028 (USD Billion)
TABLE NO. 17. North America Cancer Drugs Market Revenue, By Country, 2016 – 2028 (USD Billion)
TABLE NO. 18. North America Cancer Drugs Market Revenue, By Cancer Therapy, 2016 – 2028 (USD Billion)
TABLE NO. 19. North America Cancer Drugs Market Revenue, By Cancer Type, 2016 – 2028 (USD Billion)
TABLE NO. 20. North America Cancer Drugs Market Revenue, By Distribution Channel, 2016 – 2028 (USD Billion)
TABLE NO. 21. U.S. Cancer Drugs Market Revenue, By Cancer Therapy, 2016 – 2028 (USD Billion)
TABLE NO. 22. U.S. Cancer Drugs Market Revenue, By Cancer Type, 2016 – 2028 (USD Billion)
TABLE NO. 23. U.S. Cancer Drugs Market Revenue, By Distribution Channel, 2016 – 2028 (USD Billion)
TABLE NO. 24. Canada Cancer Drugs Market Revenue, By Cancer Therapy, 2016 – 2028 (USD Billion)
TABLE NO. 25. Canada Cancer Drugs Market Revenue, By Cancer Type, 2016 – 2028 (USD Billion)
TABLE NO. 26. Canada Cancer Drugs Market Revenue, By Distribution Channel, 2016 – 2028 (USD Billion)
TABLE NO. 27. Mexico Cancer Drugs Market Revenue, By Cancer Therapy, 2016 – 2028 (USD Billion)
TABLE NO. 28. Mexico Cancer Drugs Market Revenue, By Cancer Type, 2016 – 2028 (USD Billion)
TABLE NO. 29. Mexico Cancer Drugs Market Revenue, By Distribution Channel, 2016 – 2028 (USD Billion)
TABLE NO. 30. Drivers for the Cancer Drugs Market: Impact Analysis
TABLE NO. 31. Restraints for the Cancer Drugs Market: Impact Analysis
TABLE NO. 32. Major Buyers of Cancer Drugs
TABLE NO. 33. Distributors/Traders List of Cancer Drugs
TABLE NO. 34. Global Cancer Drugs Market, Company Market Revenue, 2016 – 2019 (USD Billion)
TABLE NO. 35. Global Cancer Drugs Market, Company Y-o-Y Growth, 2017 – 2019 (USD Billion)

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Cancer Drugs market. Zion Research has collected and analyzed key data belong to the global Cancer Drugs market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Cancer Drugs across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Cancer Drugs industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Cancer Drugs market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Cancer can be defined as uncontrolled growth of the cell. Cancer starts when cells grow out of control and outnumber normal cells. Uncontrolled growth of cell leads to the formation of the tumor which can interfere with the nervous, digestive, and circulatory systems. Tumor cell releases hormones that alter body functions. Tumors that stay in one location and show limited growth are considered as benign cancer. Whereas, the cancerous cell which flows throughout the body part, using blood, lymph, and destroying the healthy tissue are called malignant cancer. According to the American Cancer Society, cancer is the second most common cause of death in the U.S. and accounts for nearly 1 of every 4 deaths. The World Health Organization estimates that, worldwide, there were 14 million new cancer cases and 8.2 million cancer-related deaths in 2012. There are over 200 different types of cancer, and each of which is classified by the type of cell that is initially affected. Various types of cancer include prostate cancer, blood cancer, lungs cancer etc. The treatment of cancer has become of prime importance owing to increase in a number of global cancer patients. Different types of drugs are administered to cancer patients depending upon therapy used to treat the patient and type of cancer.

Growing incidences of target disease such as lung cancer, breast cancer, cervical cancer, etc. are expected to be the major driver for the global cancer drugs market. In addition, increasing research and development on biological and targeted drug therapies for the treatment of cancer coupled along with the expiration of patents is expected to trigger the growth of global cancer drugs industry in the coming years. However, the high price of drug development and stringent regulatory policies coupled along with the possibility of failure may pose the challenge to cancer drugs market. Nevertheless, increasing focus on personalized medicine coupled along with huge investment in anti-cancer drugs research across the globe are expected to act an opportunity for cancer drugs market in near future.

Global Cancer Drugs Market

Based on therapeutics, cancer drugs market has been segmented into immunotherapy, targeted therapy, chemotherapy, hormone therapy and others. Immunotherapy segment is expected to grow at the fastest rate during the forecast period. The cancer drugs market is segmented based on cancer type into breast cancer, blood cancer, gastrointestinal cancer, prostate cancer, skin cancer, lung cancer and others  In terms of revenue, blood cancer segment dominated the market in 2015.  

North America is expected to remain the dominant region over the forecast period. Increasing healthcare awareness is expected to boost the market in this region. Europe was the second largest market followed by Asia-Pacific. North America is expected to show fastest growth rate during the forecast period while Asia-Pacific market is projected to grow at a moderate rate during the forecast period. The Middle East and Africa, and Latin America are also expected to experience noticeable growth in the years to come.

Some of the key players in cancer drugs market include Bayer, GlaxoSmithKline, Novartis, Sanofi and Pfizer, Amgen, Merck, Bristol-Myers Squibb, Celgene Corporation, Ariad Pharmaceuticals, Eli Lilly, Hoffmann-La Roche Ltd, Boehringer Ingelheim GmbH, Johnson and Johnson and Teva Pharmaceuticals among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The Cancer Drugs market was valued at USD xxxx Billion in 2020.

The Cancer Drugs market is forecasted to reach USD xxxx Billion by 2028, growing at a CAGR of xx% between 2021 to 2028.

Some of the key factors driving the Cancer Drugs market growth are growing cancer cases, increased public awareness, increased spending of disposable income, drugs development and therapies for cancer and government help to improve healthcare condition are expected to drive the market for cancer drugs.

On the basis of geography, North America, followed by Europe holds a majority of xx% share backed by extensive government support for the field of drug development and is expected to withhold the supremacy in the coming years.  With promising healthcare facility and favorable insurance schemes, the cancer market is most fruitful in the North America and Europe.

A few lead players in the cancer drugs market are Amgen, Bayer Healthcare AG, CELGENE CORPORATION, GlaxoSmithKline, ARIAD Pharmaceuticals, Inc., Eli Lilly and Company, Novartis, Hoffmann-La Roche Ltd., AstraZeneca, Boehringer Ingelheim GmbH, Pfizer and Teva Pharmaceuticals Industries.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed